KMR Group, a leader in analysing R&D performance data for the biopharmaceutical R&D industry, recently concluded an assessment of global Industry site contract cycle times. The study evaluated 20,000 recently executed contracts for Phase II and III trials from leading biopharmaceutical companies.
KMR Group’s Site Contracts Study found that overall site contract cycle times have doubled from an Industry median of about 1.5 months in 2010-2011 to more than 3 months in 2014-2015. Even contracts conducted in North America, traditionally a top performer, have increased from 1.3 in 2010-11 to 2.4 in 2014–2015.
Emerging markets continue to have longer cycle times. Additionally, oncology trials typically have the longest site contracts cycle time compared with trials for other therapy areas.
The study examined site contract performance in many ways, comparing study phase, type of site (independent, institution), budget cycle time, regulatory document cycle time, therapy area, region and country level performance, and use of master agreements.
The analysis showed each company’s performance ranked against other major companies in the Industry, and it also provided context on more qualitative site contracting practices such as outsourcing use, payment strategies, timing, and terms.
“This type of information is invaluable for setting study timelines, as well as assessing areas of performance opportunity. The study gave participants reliable benchmarks and detailed company performance information that they can directly incorporate into site contracting strategies,” commented Melissa Hutchens, Senior Consultant at KMR Group.